Oral Wegovy sales hit DKK 2.26B in Q1, beating expectations
US list prices for Wegovy/Ozempic cut 35-50% from 2027
Q1 sales up 32% to DKK 96.8B, adjusted profit DKK 32.9B
2026 outlook raised to 4-12% sales decline amid pressures
Intensifying rivalry with Eli Lilly, stock down 3.8% on concerns